Serological and Molecular Evaluation of Toxoplasma gondii in Patients with Colorectal Cancer
Abstract
Background: Toxoplasma gondii is an obligate intracellular protozoan parasite that causes severe disease in immunocompromised individuals. The relationship between this parasite and cancer is complex, as the infection may either promote cancer progression or exert antitumor effects. Colorectal cancer (CRC) is one of the most common cancers. This case–control study aimed to evaluate the serological and molecular prevalence of T. gondii infection in patients with colorectal cancer.
Methods: The study was conducted at Mashhad teaching hospitals, Khoran Razavi Province, Iran from Sep 2021 to Mar 2023, involving 156 participants. This included 78 people with CRC and 78 people without cancer, whose biopsy samples were subjected to pathological evaluations to detect cancer. Serological tests for anti-Toxoplasma IgG and IgM antibodies were performed using ELISA. Molecular tests utilized PCR analysis of biopsy samples to detect T. gondii DNA.
Results: 52.6% of CRC patients tested positive for anti-Toxoplasma IgG, compared with 46.2% in the control group. However, this difference was not statistically significant (P=0.423). Only one patient in the CRC group tested positive for IgM, indicating a recent infection. Molecular analysis did not detect any T. gondii DNA in the tumoral and normal tissues. Environmental risk factors associated with IgG positivity included living in rural areas, exposure to cats, and consumption of spring water.
Conclusion: Our study found no significant association between CRC and T. gondii infection. Though limitations such as small sample size and lack of Immunohistochemistry (IHC) warrant further investigation.
2. Azami SJ, Teimouri A, Keshavarz H, et al. Curcumin nanoemulsion as a novel chemical for the treatment of acute and chronic toxoplasmosis in mice. Int J Nanomedicine. 2018; 13:7363-7374.
3. Azami SJ, Amani A, Keshavarz H, et al. Nanoemulsion of atovaquone as a promising approach for treatment of acute and chronic toxoplasmosis. Eur J Pharm Sci. 2018;117:138-46.
4. Goudarzi F, Jajarmi V, Shojaee S, Mohebali M, Keshavarz H. Formulation and evaluation of atovaquone-loaded macrophage-derived exosomes against Toxoplasma gondii: in vitro and in vivo assessment. Microbiol Spectr. 2024;12(1):e03080-23.
5. Elmore SA, Jones JL, Conrad PA, Patton S, Lindsay DS, Dubey JP. Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention. Trends Parasitol. 2010;26(4):190-6.
6. Cai Y, Chen H, Jin L, You Y, Shen J. STAT3-dependent transactivation of miRNA genes following Toxoplasma gondii infection in macrophage. Parasit Vectors. 2013;6:356.
7. Denkers EY, Bzik DJ, Fox BA, Butcher BA. An inside job: hacking into Janus kinase/signal transducer and activator of transcription signaling cascades by the intracellular protozoan Toxoplasma gondii. Infect Immun. 2012;80(2):476-82.
8. Caner A. Toxoplasma gondii could have a possible role in the cancer mechanism by modulating the host's cell response. Acta Trop. 2021;220:105966.
9. Hunter CA, Yu D, Gee M, Ngo CV, et al. Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immunol. 2001;166(10):5878-81.
10. Lotfalizadeh N, Sadr S, Morovati S, et al. A potential cure for tumor-associated immunosuppression by Toxoplasma gondii. Cancer Rep (Hoboken). 2024;7(2):e1963.
11. Abdollahi A, Razavian I, Razavian E, et al. Toxoplasma gondii infection/exposure and the risk of brain tumors: A systematic review and meta-analysis. Cancer Epidemiol. 2022;77:102119.
12. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78-85.
13. Bayazid AA, Sutradhar S, Harun AB, et al. Molecular Insights into the Detection and Genotyping of Toxoplasma gondii. Current Clinical Microbiology Reports. 2026; 13(1):10.
14. Chen J, Liao W, Peng H. Toxoplasma gondii infection possibly reverses host immunosuppression to restrain tumor growth. Front Cell Infect Microbiol. 2022;12:959300.
15. Fox BA, Sanders KL, Bzik DJ. Non-replicating Toxoplasma gondii reverses tumor-associated immunosuppression. Onc-oimmunology. 2013;2(11):e26296.
16. Pyo KH, Lee YW, Lim SM, Shin EH. Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice. Oncotarget. 2016;7(45):74107-19.
17. Yarovinsky F, Zhang D, Andersen JF, et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science. 2005;308(5728):1626-9.
18. Baird JR, Byrne KT, Lizotte PH, et al. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol. 2013;190(1):469-78.
19. Jiao YM, Zhang L, Ge YY, Liang YJ, Yong W. [Effects of excreted/secreted antigens of Toxoplasma gondii on CD4+ CD25+ Foxp3+ T cells and NK cells of melanoma-bearing mice]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2011;23(3):301-6.
20. Xu LQ, Yao LJ, Jiang D, et al. A uracil auxotroph Toxoplasma gondii exerting immunomodulation to inhibit breast cancer growth and metastasis. Parasit Vectors. 2021;14(1):601.
21. Baird JR, Fox BA, Sanders KL, et al. Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res. 2013;73(13):3842-51.
22. Bahwal SA, Chen JJ, E L, Hao T, et al. Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model. J Cancer Res Clin Oncol. 2022;148(10):2743-57.
23. Sanders KL, Fox BA, Bzik DJ. Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations. Cancer Immunol Res. 2015;3(8):891-901.
24. Sanders KL, Fox BA, Bzik DJ. Attenuated Toxoplasma gondii therapy of disseminated pancreatic cancer generates long-lasting immunity to pancreatic cancer. Oncoimmunology. 2015;5(4):e1104447.
25. Kim JO, Jung SS, Kim SY, et al. Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis. J Korean Med Sci. 2007; 22 Suppl(Suppl):S38-46..
26. Seo SH, Kim SG, Shin JH, Ham DW, Shin EH. Toxoplasma GRA16 Inhibits NF-κB Activation through PP2A-B55 Upregulation in Non-Small-Cell Lung Carcinoma Cells. Int J Mol Sci. 2020;21(18):6642.
27. Suzuki Y, Kobayashi A. Antitumor effect of intralesional injection with formalin-fixed Toxoplasma gondii organisms on Lewis lung carcinoma in Toxoplasma-infected mice. Cancer Lett. 1985;25(3):247-54.
28. Yu-Meng J, Zhi-Yong T, Yu-Jian C, et al. [Inhibition of Toxoplasma gondii excretory - secretory antigens on growth of murine Lewis lung carcinoma]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2019;31(4):400-403.
29. World Health Organization. (n.d.). Colorectal cancer fact sheet. Retrieved October 13, 2024, from https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer
30. American Cancer Society. Colorectal Cancer Facts & Figures 2023-2025. Atlanta, GA.
31. Homan WL, Vercammen M, De Braekeleer J, et al. Identification of a 200- to 300-fold repetitive 529 bp DNA fragment in Toxoplasma gondii, and its use for diagnostic and quantitative PCR. Int J Parasitol. 2000;30(1):69-75.
32. Lin MH, Chen TC, Kuo TT, et al. Real-time PCR for quantitative detection of Toxoplasma gondii. J Clin Microbiol. 2000;38(11):4121-5.
33. Costa JM, Pautas C, Ernault P, et al. Real-time PCR for diagnosis and follow-up of Toxoplasma reactivation after allogeneic stem cell transplantation using fluorescence resonance energy transfer hybridization probes. J Clin Microbiol. 2000;38(8):2929-32.
34. Cassaing S, Bessières MH, Berry A, et al. Comparison between two amplification sets for molecular diagnosis of toxoplasmosis by real-time PCR. J Clin Microbiol. 2006; 44(3):720-4.
35. Edvinsson B, Lappalainen M, Evengård B. Real-time PCR targeting a 529-bp repeat element for diagnosis of toxoplasmosis. Clin Microbiol Infect. 2006;12(2):131-6.
36. Berizi M, Babaie J, Fard-Esfahani P, et al. Development of a Quantitative Real-Time PCR Assay for Detection of Toxoplasma gondii in Brain Samples. Iran J Parasitol. 2021;16(4):621-30.
37. Wu W, Chen Q, Zou W, et al. Toxoplasma gondii bradyzoite-specific BAG1 is nonessential for cyst formation due to compensation by other heat-shock proteins. Parasit Vectors. 2024;17(1):322.
38. Jones CD, Okhravi N, Adamson P, Tasker S, Lightman S. Comparison of PCR detection methods for B1, P30, and 18S rDNA genes of T. gondii in aqueous humor. Invest Ophthalmol Vis Sci. 2000;41(3):634-44.
39. Yu H, Huang B, Zhuo X, Chen X, Du A. Evaluation of a real-time PCR assay based on the single-copy SAG1 gene for the detection of Toxoplasma gondii. Vet Parasitol. 2013;197(3-4):670-3.
40. Anvari D, Sharif M, Sarvi S, et al. Seroprevalence of Toxoplasma gondii infection in cancer patients: A systematic review and meta-analysis. Microb Pathog. 2019;129:30-42.
41. Ahmed D, Saheb E. The Association of Toxoplasma gondii Infection in Breast and Colorectal Cancer Patients. Int J Clin Oncol Cancer Res. 2017;2:86-92.
42. Yu Y, Guo D, Qu T, et al. Increased risk of Toxoplasma gondii infection in patients with colorectal cancer in eastern China: Seroprevalence, risk factors, and a case–control study. Biomed Res Int. 2020;2020:2539482.
| Files | ||
| Issue | Vol 21 No 4 (2026) | |
| Section | Original Article(s) | |
| Keywords | ||
| Toxoplasma gondii Colorectal cancer Seroprevalence Polymerase chain reaction (PCR) | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |

